Quisinostat
Chemical compound
- None
- N-Hydroxy-2-[4-({[(1-methyl-1H-indol-3-yl)methyl]amino}methyl)-1-piperidinyl]-5-pyrimidinecarboxamide
- 875320-29-9 Y
- 11538455
- 9713236
- 9BJ85K1J8S
- D10321
- CHEBI:94771
- DTXSID90236376
- Interactive image
- O=C(NO)c1cnc(nc1)N2CCC(CC2)CNCc4c3ccccc3n(c4)C
InChI
- InChI=1S/C21H26N6O2/c1-26-14-17(18-4-2-3-5-19(18)26)11-22-10-15-6-8-27(9-7-15)21-23-12-16(13-24-21)20(28)25-29/h2-5,12-15,22,29H,6-11H2,1H3,(H,25,28)
- Key:PAWIYAYFNXQGAP-UHFFFAOYSA-N
Quisinostat (USAN;[2] development code JNJ-26481585) is an experimental drug candidate for the treatment of cancer. It is a "second generation" histone deacetylase inhibitor with antineoplastic activity.[3][4][5] It is highly potent against class I and II HDACs.[6]
History
It was developed by Janssen Pharmaceuticals and licensed to NewVac LLC.[7]
Preclinical studies show that quisinostat amplifies HDAC-repressed expression of E-cadherin, leading to a reversal of epithelial to mesenchymal transition in tumor cells.[7]
Clinical trials
Results of a phase I trials in patients with multiple myeloma in combination with bortezomib and dexamethasone were published in 2016.[8]
References
- ^ "NCI Drug Dictionary". National Cancer Institute. 2 February 2011.
- ^ "Quisinostat" (PDF). American Medical Association.
- ^ Tong WG, Wei Y, Stevenson W, Kuang SQ, Fang Z, Zhang M, et al. (February 2010). "Preclinical antileukemia activity of JNJ-26481585, a potent second-generation histone deacetylase inhibitor". Leukemia Research. 34 (2): 221–8. doi:10.1016/j.leukres.2009.07.024. PMID 19682743.
- ^ Stühmer T, Arts J, Chatterjee M, Borawski J, Wolff A, King P, et al. (May 2010). "Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585". British Journal of Haematology. 149 (4): 529–36. doi:10.1111/j.1365-2141.2010.08126.x. PMID 20331455. S2CID 42077659.
- ^ "Quisinostat". NCI Drug Dictionary. National Cancer Institute.
- ^ Carol H, Gorlick R, Kolb EA, Morton CL, Manesh DM, Keir ST, et al. (February 2014). "Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program". Pediatric Blood & Cancer. 61 (2): 245–52. doi:10.1002/pbc.24724. PMC 4225045. PMID 24038993.
- ^ a b LLC, NewVac. "NewVac Reports Primary Endpoint Met in Phase II Clinical Trial of Quisinostat in Combination with Paclitaxel and Carboplatin in Platinum-Resistant Ovarian Cancer". www.prnewswire.com.
- ^ Moreau P, Facon T, Touzeau C, Benboubker L, Delain M, Badamo-Dotzis J, et al. (July 2016). "Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma". Leukemia & Lymphoma. 57 (7): 1546–59. doi:10.3109/10428194.2015.1117611. PMID 26758913. S2CID 42026457.
- v
- t
- e
- 3,3'-Diindolylmethane
- β-Hydroxybutyric acid (β-hydroxybutyrate)
- Abexinostat
- Acetoacetic acid (acetoacetate)
- Allyl mercaptan
- Apicidin
- Belinostat
- Butyric acid (butyrate)
- Capsaicin
- Citarinostat
- Curcumin
- Diallyl disulfide
- Entinostat
- Fimepinostat
- Givinostat
- Indole-3-carbinol
- Kevetrin
- Martinostat
- Mocetinostat
- Niacinamide
- Panobinostat
- Parthenolide
- Phenylbutyrate
- Pracinostat
- Quisinostat
- Resminostat
- Romidepsin
- Scriptaid
- Sodium butyrate
- Sodium oxybate (GHB sodium)
- Sodium phenylbutyrate
- Sodium valproate
- Sulforaphane
- Trapoxin B
- Trichostatin A
- Tucidinostat
- Valnoctamide
- Valproic acid (valproate)
- Valproate pivoxil
- Valproate semisodium
- Valpromide
- Vorinostat (SAHA)
See also: Receptor/signaling modulators